Sinus bradycardia, or a slow heart rate, can be a sign of cardiovascular health in healthy young adults and endurance athletes. It can also be a sign of an underlying condition requiring medical ...

The last time I wrote about Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) it was in a Seeking Alpha article entitled "Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't The Only Catalyst On Deck." ...

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on Monday released topline results from the pivotal Phase 3 TRANSCEND trial evaluating setmelanotide, a melanocortin-4 receptor (MC4R) agonist, for the ...

The investigational drug is being developed as a prescription medication to convert acute episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The FDA’s CRL did not ...

The Montreal biopharmaceutical company, which was seeking FDA approval of etripamil for the conversion of acute episodes of paroxysmal supraventricular tachycardia, or PSVT, to sinus rhythm in ...

a prescription medication in development for the conversion of acute episodes of PSVT to sinus rhythm in adults. The FDA did not raise any concerns regarding etripamil clinical safety or efficacy ...

During today's Nintendo Direct, Rhythm Heaven Groove, a brand-new installment in the Rhythm Heaven series, was announced. The rhythm-game series hasn't seen a new title since 2015's Rhythm Heaven ...

Expectedly, the Direct featured a number of release dates for new Switch games, but it also showcased new Metroid Prime 4: Beyond gameplay and revealed new Rhythm Heaven and Tomodachi Life games. You ...